Posted innews OB/GYN & Women's Health Specialties
FDA Extends Review of Bayer’s Elinzanetant for Menopause Symptoms
The FDA delays its review of Bayer's elinzanetant, a novel treatment for menopause-related vasomotor symptoms, by 90 days, citing the need for additional data assessment.